1
|
van der Velden YU, Grobben M, Caniels TG, Burger JA, Poniman M, Oomen M, Rijnstra ESV, Tejjani K, Guerra D, Kempers R, Stegmann T, van Gils MJ, Sanders RW. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. Sci Rep 2022; 12:3884. [PMID: 35273217 PMCID: PMC8913678 DOI: 10.1038/s41598-022-07590-w] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 02/15/2022] [Indexed: 12/24/2022] Open
Abstract
Current SARS-CoV-2 vaccines are effective, but long-term protection is threatened by the emergence of virus variants. We generated a virosome vaccine containing the Beta spike protein and compared its immunogenicity in mice to a virosome vaccine containing the original Wuhan spike. Two administrations of the virosomes induced potent SARS-CoV-2 neutralizing antibodies in both vaccine groups. The level of autologous neutralization in Beta-vaccinated mice was similar to the level of autologous neutralization in Wuhan-vaccinated mice. However, heterologous neutralization to the Wuhan strain in Beta-vaccinated mice was 4.7-fold lower than autologous neutralization, whereas heterologous neutralization to the Beta strain in Wuhan-vaccinated mice was reduced by only 1.9-fold compared to autologous neutralization levels. In addition, neutralizing activity against the D614G, Alpha and Delta variants was also significantly lower after Beta spike vaccination than after Wuhan spike vaccination. Our results show that Beta spike vaccination induces inferior neutralization breadth. These results are informative for programs aimed to develop broadly active SARS-CoV-2 vaccines.
Collapse
Affiliation(s)
- Yme U van der Velden
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Marloes Grobben
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Tom G Caniels
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Judith A Burger
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Meliawati Poniman
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Melissa Oomen
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Esther Siteur-van Rijnstra
- Experimental Immunology, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Khadija Tejjani
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Denise Guerra
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Ronald Kempers
- Mymetics BV, JH Oortweg 21, 2333 CH, Leiden, The Netherlands
| | - Toon Stegmann
- Mymetics BV, JH Oortweg 21, 2333 CH, Leiden, The Netherlands
| | - Marit J van Gils
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Rogier W Sanders
- Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands.
- Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY, 10065, USA.
| |
Collapse
|
2
|
Röhn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, Kopf M, Bachmann MF. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2007; 36:2857-67. [PMID: 17048275 DOI: 10.1002/eji.200636658] [Citation(s) in RCA: 164] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Interleukin 17 is a T cell-derived cytokine that induces the release of pro-inflammatory mediators in a wide range of cell types. Recently, a subset of IL-17-producing T helper cells (Th17) distinct from Th1 and Th2 cells has been described, which constitutes a new T cell polarization state. Aberrant Th17 responses and overexpression of IL-17 have been implicated in a number of autoimmune disorders including rheumatoid arthritis and multiple sclerosis. Molecules blocking IL-17 such as IL-17-specific monoclonal antibodies have proved to be effective in ameliorating disease in animal models. Hitherto, active immunization targeting IL-17 is an untried approach. Herein we explore the potential of neutralizing IL-17 by active immunization using virus-like particles conjugated with recombinant IL-17 (IL-17-VLP). Immunization with IL-17-VLP induced high levels of anti-IL-17 antibodies thereby overcoming natural tolerance, even in the absence of added adjuvant. Mice immunized with IL-17-VLP had lower incidence of disease, slower progression to disease and reduced scores of disease severity in both collagen-induced arthritis and experimental autoimmune encephalomyelitis. Active immunization against IL-17 therefore represents a novel therapeutic approach for the treatment of chronic inflammatory diseases.
Collapse
Affiliation(s)
- Till A Röhn
- Cytos Biotechnology AG, Immunodrugs, Zürich, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Sonderegger I, Röhn TA, Kurrer MO, Iezzi G, Zou Y, Kastelein RA, Bachmann MF, Kopf M. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2007; 36:2849-56. [PMID: 17039570 DOI: 10.1002/eji.200636484] [Citation(s) in RCA: 128] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The most common reason for heart failure in young adults is dilated cardiomyopathy often resulting from myocarditis. Clinical studies and animal models provide evidence that an autoimmune response against heart myosin is the underlying reason for the disease. IL-12 has been suggested to play a key role in development of experimental autoimmune myocarditis (EAM), as IL-12p40 and IL-12Rbeta1 knockouts are protected from disease. In this study, we have compared IL-12p40-/- mice, IL-12p35-/- mice and mice treated with a neutralizing IL-23 antibody in EAM and found that in fact IL-23, not IL-12, is responsible for inflammatory heart disease. However, these cytokines appear to have redundant activity for priming and expansion of autoreactive CD4 T cells, as specific T cell proliferation was only defective in the absence of both cytokines. IL-23 has been suggested to promote a pathogenic IL-17-producing T cell population. We targeted IL-17 by capitalizing on an active vaccination approach that effectively breaks B cell tolerance. Neutralization of IL-17 reduced myocarditis and heart autoantibody responses, suggesting that IL-17 is the critical effector cytokine responsible for EAM. Thus, targeting of IL-23 and IL-17 by passive and active vaccination strategies holds promise as a therapeutic approach to treat patients at risk for development of dilated cardiomyopathy.
Collapse
Affiliation(s)
- Ivo Sonderegger
- Institute of Integrative Biology, Molecular Biomedicine, ETH Zürich, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Cusi MG, Del Vecchio MT, Terrosi C, Savellini GG, Di Genova G, La Placa M, Fallarino F, Moser C, Cardone C, Giorgi G, Francini G, Correale P. Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine. J Immunol 2005; 174:7210-6. [PMID: 15905566 DOI: 10.4049/jimmunol.174.11.7210] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The correct interaction of a costimulatory molecule such as CD40L with its contrareceptor CD40 expressed on the membrane of professional APCs, provides transmembrane signaling that leads to APC activation. This process can be exploited to significantly improve the efficacy of cancer vaccines and the outcome of a possible cancer vaccine-induced, Ag-specific CTL response. Therefore, we investigated whether a novel intranasal delivery of immune-reconstituted influenza virosomes (IRIV), assembled with the CD40L gene (CD40L/IRIV), could be used to improve protective immunity and the Ag-specific CTL response against carcinoembryonic Ag (CEA) generated with a novel vaccine constituted of IRIV assembled with the CEA gene (CEA/IRIV). Our results suggest that CD40L/IRIV was able to augment CEA-specific CTL activity and CEA-specific protective immunity induced by CEA/IRIV most likely through the induction of a CTL response associated with a Th1 phenotype. In conclusion, we provide evidence that CD40L/IRIV, by acting through the CD40L/CD40 signaling pathway, acts as an immune-adjuvant that could increase the efficacy of a CEA-specific cancer vaccine, which could provide an efficacious new strategy for cancer therapy.
Collapse
MESH Headings
- Adjuvants, Immunologic/chemical synthesis
- Adjuvants, Immunologic/genetics
- Adjuvants, Immunologic/therapeutic use
- Animals
- Antigens, CD/biosynthesis
- Antigens, CD/physiology
- B7-1 Antigen/biosynthesis
- B7-1 Antigen/physiology
- B7-2 Antigen
- CD40 Ligand/genetics
- CD40 Ligand/immunology
- CD40 Ligand/therapeutic use
- Cancer Vaccines/chemical synthesis
- Cancer Vaccines/genetics
- Cancer Vaccines/immunology
- Cancer Vaccines/therapeutic use
- Carcinoembryonic Antigen/immunology
- Carcinoembryonic Antigen/therapeutic use
- Cell Line, Tumor
- Cells, Cultured
- Cytotoxicity, Immunologic/genetics
- Epitopes, T-Lymphocyte/immunology
- Epitopes, T-Lymphocyte/therapeutic use
- Female
- Influenza Vaccines/chemical synthesis
- Influenza Vaccines/genetics
- Influenza Vaccines/immunology
- Influenza Vaccines/therapeutic use
- Membrane Glycoproteins/biosynthesis
- Membrane Glycoproteins/physiology
- Mice
- Mice, Inbred BALB C
- T-Lymphocytes, Cytotoxic/immunology
- Th1 Cells/immunology
- Th1 Cells/metabolism
- Transfection
- Vaccines, Combined/chemical synthesis
- Vaccines, Combined/genetics
- Vaccines, Combined/immunology
- Vaccines, Combined/therapeutic use
- Vaccines, Virosome/chemical synthesis
- Vaccines, Virosome/genetics
- Vaccines, Virosome/immunology
- Vaccines, Virosome/therapeutic use
Collapse
Affiliation(s)
- Maria Grazia Cusi
- Virology Section, Department of Molecular Biology, Siena University School of Medicine, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Reincke M, Ortmann D, Hausmann J, Beuschlein F. Cytotoxic T-cell response against steroidogenic acute regulatory protein using DNA vaccination followed by vaccinia virus infection in a mouse adrenal carcinoma model. Horm Metab Res 2004; 36:411-4. [PMID: 15241733 DOI: 10.1055/s-2004-814571] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Adrenocortical carcinoma (ACC) is still one of the most devastating human tumors with a five year survival as low as 20 %. In a previous study, we showed that DNA vaccination followed by vaccinia virus was able to break immune tolerance against murine steroidogenic acute regulatory (mStAR). Prophylactic vaccination in syngenic mice resulted in protective immunity against Sp2-0 tumor cells expressing mStAR. However, approximately a third of the animals developed tumors despite vaccination. This prompted us to investigate whether vaccination failure is responsible for this phenomenon. BALB/cBALB/c mice (in groups of 6 - 9 animals) were vaccinated intramuscularly by injection of cDNA expression vectors encoding mStAR three times at weekly intervals. This was followed by a recombinant vaccinia virus (rVV-mStAR) infection to boost immune response. Ten days after the last vaccination, Sp2-mStAR or parental Sp2-0 cells (as controls) were injected s. c. Tumor development was monitored by daily palpation. Approximately two weeks later, the animals were sacrificed and the spleens removed. After restimulation with the cell lines expressing mStAR, the splenocytes were tested for presence of mStAR self-reactive cytotoxic T-lymphocytes using ELISPOT analysis. With this approach, we were able to show that those animals protected from tumor growth had a specific T-cell response against StAR whereas mice without a specific T-cell response developed Sp2-mStAR tumors. Our data demonstrate that vaccination failure, probably due to the low antigenicity of mStAR, is responsible for tumor growth in our model system.
Collapse
Affiliation(s)
- M Reincke
- Medizinische Klinik-Innenstadt, Klinikum der Maximilians-Ludwigs-Universität München, Ziemssenstrasse 1, 80336 Munich, Germany.
| | | | | | | |
Collapse
|
6
|
Abstract
Inflexal V, a novel virosome-based trivalent influenza vaccine, has been shown to be highly immunogenic and well tolerated in children, young adults, and the elderly. Here we discuss the techniques for the manufacture of Inflexal V, highlighting the purity and consistency of the manufacturing process. Key factors to be taken into account in the construction of Inflexal V are the retention of the natural presentation of antigens, its biodegradability and the presentation of few adverse events. The constituents of the vaccine were also carefully considered based on suitability for human use, adjuvanticity and an innate lack of toxicity.
Collapse
Affiliation(s)
- Robert Mischler
- Berna Biotech Ltd., Rehhagstr. 79, CH-3018 Berne, Switzerland.
| | | |
Collapse
|
7
|
Abstract
The desire for improved quality of life in both industrialised and under-developed nations has led to the quest for greater understanding and subsequent prevention and treatment of diseases. Here we discuss some of the latest of modern medicine's approaches to vaccination and disease treatment. Our main subject of discussion being the novel antigen delivery systems termed immunopotentiating reconstituted influenza virosomes (IRIVs) and their use as vaccines. Particular attention is paid to the currently licensed Epaxal and Inflexal V, good examples of the improvements being made in vaccinology. Alternative uses of virosomes such as peptide delivery, cytosolic drug delivery and gene delivery are also considered, highlighting the flexibility of the IRIV formulation and method of action. The paper concludes with consideration of alternative novel approaches to vaccinology including bacterial carriers for DNA vaccines, recombinant MV vaccines and polysaccharide-protein conjugates.
Collapse
Affiliation(s)
- R Glück
- Berna Biotech Ltd., Rehhagstr. 79, CH-3018 Berne, Switzerland.
| | | |
Collapse
|
8
|
Marchisio P, Cavagna R, Maspes B, Gironi S, Esposito S, Lambertini L, Massimini A, Herzog C, Principi N. Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children. Clin Infect Dis 2002; 35:168-74. [PMID: 12087523 DOI: 10.1086/341028] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2001] [Revised: 02/25/2002] [Indexed: 11/04/2022] Open
Abstract
To evaluate the efficacy of an intranasal, inactivated, virosomal subunit influenza vaccine for prevention of new episodes of acute otitis media (AOM) in children with recurrent AOM, 133 children aged 1-5 years were randomized to receive the vaccine (n=67) or no vaccination (n=66). During a 6-month period, 24 (35.8%) vaccine recipients had 32 episodes of AOM; 42 (63.6%) control subjects had 64 episodes. The overall efficacy of vaccination in preventing AOM was 43.7% (95% confidence interval, 18.6-61.1; P=.002). Children vaccinated before influenza season had a significantly better outcome than did those vaccinated after the onset of influenza season. The cumulative duration of middle ear effusion was significantly less in vaccinated children than in control subjects. Data suggest that the intranasal virosomal influenza vaccine might be considered among the options for the prevention of AOM in children <5 years old with recurrent AOM.
Collapse
MESH Headings
- Acute Disease
- Administration, Intranasal
- Child, Preschool
- Female
- Follow-Up Studies
- Humans
- Immunization Schedule
- Infant
- Influenza A virus/immunology
- Influenza Vaccines/administration & dosage
- Influenza Vaccines/adverse effects
- Influenza Vaccines/therapeutic use
- Influenza, Human/epidemiology
- Influenza, Human/prevention & control
- Male
- Otitis Media/epidemiology
- Otitis Media/prevention & control
- Otitis Media with Effusion/epidemiology
- Otitis Media with Effusion/prevention & control
- Prospective Studies
- Recurrence
- Respiratory Tract Diseases/epidemiology
- Respiratory Tract Diseases/prevention & control
- Single-Blind Method
- Treatment Outcome
- Vaccines, Subunit/administration & dosage
- Vaccines, Subunit/adverse effects
- Vaccines, Subunit/therapeutic use
- Vaccines, Virosome/administration & dosage
- Vaccines, Virosome/adverse effects
- Vaccines, Virosome/therapeutic use
Collapse
Affiliation(s)
- Paola Marchisio
- Pediatric Department 1, University of Milan, 20122 Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Hunziker IP, Zurbriggen R, Glueck R, Engler OB, Reichen J, Dai WJ, Pichler WJ, Cerny A. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol Immunol 2001; 38:475-84. [PMID: 11741697 DOI: 10.1016/s0161-5890(01)00083-9] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Hepatitis C virus (HCV) is a widespread infectious disease in humans with the negative implication of becoming chronic in most persons. Patients infected with HCV are at risk of liver cirrhosis or hepatocellular carcinoma at later stages. In contrast to hepatitis A and hepatitis B, there is no immunization yet available, neither prophylactic nor therapeutic. Thus, there is an urgent need to develop a safe, protective vaccine against this fatal disease. Developing countries are even more at risk for HCV. There are currently a number of scientific approaches aimed towards solving this problem. Taking both risks and costs of immunization into consideration, a peptide-based vaccine may be a reasonable prophylactic protection. Also, it might be of therapeutic use in already infected patients by increasing a specific CTL response against HCV. In our lab, we are focusing on immunopotentiating reconstituted influenza virosomes (IRIVs) as carriers for immunogenic HLA-A2-restricted core epitopes to induce peptide-specific cytotoxic T lymphocytes (CTLs). The IRIVs are similar to liposomes, but in addition contain influenza-derived hemagglutinin and neuraminidase on their outer surface which makes them fusogenic, thus, permitting antigen delivery to host cells. So far, virosomes have been successfully used for vaccine development and as a result a virosomal vaccine against both influenza virus (Inflexal) BERNA) and hepatitis A virus (HAV) (Epaxal) BERNA) already exist on the market. This paper focuses on the importance of development of a successful vaccine against HCV and, more specifically, we discuss the use, advantages and disadvantages of a peptide-based vaccine. A brief report of our latest findings will be included.
Collapse
Affiliation(s)
- I P Hunziker
- Clinic of Rheumatology and Clinical Immunology/Allergology, University Hospital, Inselspital Bern, 3010, Bern, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|